Skip to main content

PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

Access & Citations

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

Online attention

Altmetric score 2
  • 2 tweeters
  • 85 Mendeley

This article is in the 46th percentile (ranked 186,710th) of the 360,037 tracked articles of a similar age in all journals and the 66th percentile (ranked 57th) of the 176 tracked articles of a similar age in BMC Cancer

View more on Altmetric

Altmetric calculates a score based on the online attention an article receives. Each coloured thread in the circle represents a different type of online attention. The number in the centre is the Altmetric score. Social media and mainstream news media are the main sources that calculate the score. Reference managers such as Mendeley are also tracked but do not contribute to the score. Older articles often score higher because they have had more time to get noticed. To account for this, Altmetric has included the context data for other articles of a similar age.